The SPRINT-1 trial was a phase-II trial of boceprevir in difficult-to-treat patients with HCV genotype 1. Study results were announced at the 44th annual meeting of the European Association for the Study of the Liver in Copenhagen in April, 2009. When used in combination with peginterferon alfa-2b and ribavirin, boceprevir resulted in significantly higher sustained viral response rates in the most difficult-to-treat patients with genotype 1. The phase-II trial compared three different regimens: four weeks of peginterferon alfa-2b plus ribavirin followed by boceprevir for 24 weeks or 44 weeks; boceprevir in combination with peginterferon alfa-2b plus ribavirin as above for 28 or 48 weeks ; and peginterferon alfa-2b plus low-dose ribavirin and boceprevir for 48 weeks. The patients enrolled in the SPRINT-1 study were among the most difficult to treat, and were exclusively those with genotype 1. Additionally, many of the patients had other difficult-to-treat indices, including cirrhosis, high viral load, and African-American ancestry. An SVR after 24 weeks off therapy of 75% was achieved in the group treated for 48 weeks with four weeks of lead-in therapy with peginterferon alfa-2b plus ribavirin followed by the addition of boceprivir. This represents a near doubling of the rate of SVR compared to standard therapy without boceprevir in this group. Anemia was the most common adverse event. It occurred in half of the patients who received boceprevir and by about a third of the patients taking peginterferon alfa-2b plus ribavirin at the standard dose. The lead investigator of the study was Dr. Paul Kwo, associate professor of medicine at the School of Medicine, Indiana University, in Indianapolis, Indiana, USA.
SPRINT-2 trial
The SPRINT-2 trial was a double-blind study which randomly assigned adults with untreated hepatitis C virus, genotype 1, to one of three groups. Each group received a month of peginterferon alfa-2b and ribavirin before being randomized to one of three arms. The first arm received placebo plus peginterferon-ribavirin for 44 weeks, the second arm received boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks, and the third arm received boceprevir plus peginterferon-ribavirin for 44 weeks. Black patients and nonblack patients were enrolled and analyzed separately, since black patients have been shown to respond less well to antiviral therapy with peginterferon plus ribavirin than nonblacks. In all, 938 nonblack and 159 black patients were enrolled in the study. At 44 weeks, among the nonblack cohort, a 40% sustained virologic response occurred in the placebo group, a 67% response in the response-guided boceprevir group, and a 68% response in the fixed-duration therapy group. Important side effects included anemia and dysgeusia.
RESPOND-2 trial
The RESPOND-2 trial studied patients with chronic hepatitis C genotype 1 who did not have a sustained response to therapy with peginterferon-ribavirin therapy. All patients received a month of peginterferon alfa-2b and ribavirin before being randomized to one of three arms. The first arm received placebo plus peginterferon-ribavirin for 44 weeks. The second group received boceprevir plus peginterferon-ribavirin for 32 weeks, and those with a detectable HCV RNA level at week 8 received peginterferon-ribavirin and placebo for another 12 weeks. The third group received boceprevir and peginterferon-ribavirin for 44 weeks. Four hundred and three people were treated in the trial. At 44 weeks, the control group had a lower sustained virologic response rate than either of the groups treated with boceprevir—59% sustained viral response for the group with response-guided therapy and 66% response for the group with fixed-duration therapy.
